+ Part VIII · The field in 2026
The field in 2026.
Materials, tests and judgments come from three layers of the field, in many countries. As of November 2026, chemical companies make the polymers and silicones that devices are made from, and three of them changed owner or status between December 2025 and May 2026. Contract laboratories run the chemistry and the biological tests, under two recognitions that answer different questions. The evaluators and toxicologists who judge the results are a role rather than a kind of firm, and the conclusion on the device is theirs. India's public testing institute and the three recognitions that India gives laboratories are described with the rest, and no maker or laboratory is ranked. The part serves two decisions in a file: which laboratory and evaluator to use, and when a change at a maker reopens the evaluation.
The field in 2026.
+ The questionWho makes the materials, runs the tests and writes the evaluations?
Three layers share the work
Three groups share the work of a biological evaluation: those who make the materials, those who test them and those who judge the results. Every page that Chapter 24 reads comes from one of them. Makers state what a resin or a silicone is and how they screened it. Laboratories measure what a device's parts release and how cells, tissue or animals respond. Evaluators set those results against the device's contacts and use, and they write the conclusion. The companies in each layer are bought, sold and renamed, so every company fact in this chapter carries its date, as of November 2026.
Material makers, dated
An evaluation is written about named materials, so a change of owner or name at a maker raises one question for it: whether the material itself changed. Covestro makes Makrolon polycarbonate and thermoplastic polyurethanes. It became majority-owned by XRG, the international investment company of ADNOC, and Covestro announced the closing of that transaction on 10 December 2025. On 30 April 2026 Elkem completed the sale of the majority of its silicones division to Bluestar, its former majority shareholder, and the business is renaming itself Bluestar Silicones in stages. A maker that changes owner may keep its product names, as the silicones business states it will, so an unchanged name does not show an unchanged material.
A change in a maker's legal status raises the same question. Trinseo makes polycarbonate among other plastics. On 26 May 2026 it opened voluntary bankruptcy cases in a US court, under Chapter 11 of the Bankruptcy Code, for itself and some of its subsidiaries, to restructure its debt. It states that it continues to operate as usual, and it had not emerged from Chapter 11 when it reported its second quarter, on 6 August 2026. The running device has a polycarbonate water chamber and mask frame and a silicone cushion (Chapter 3). Its plan records each material by grade and supplier (Chapter 22). After such a change the device maker asks the supplier whether the formulation, its additives or the plant changed, and the answer, recorded against the material, decides whether the evaluation is reopened (Chapter 23).
Makers also describe their new materials, and the descriptions are the makers' own. On 3 February 2026 DuPont launched Liveo C6-8XX, two-part liquid silicone rubbers for parts that are not implanted or are implanted for less than 30 days. The series meets USP Class VI, the certificate of Chapter 3, and was "tested according to ISO 10993 standards", in DuPont's statements. Lubrizol launched Tolerathane, a thermoplastic polyurethane for implanted devices such as cardiac leads, and claims for it "superior tolerance to oxidative and hydrolytic attack compared to currently available TPU materials", as trade press reported on 11 February 2026. A material that its maker tested to ISO 10993 still leaves the finished device to be evaluated (Chapter 3).
Laboratories and their two recognitions
Contract laboratories run the chemistry of Chapters 12 and 13 and the biological tests of Chapter 18 on device makers' behalf, and their layer is consolidating. On 28 February 2025 NAMSA, a contract laboratory, completed its purchase of WuXi AppTec's US device-testing business, whose sites are in Atlanta, Georgia, and St. Paul, Minnesota. In January 2026 trade press reported NAMSA's acquisition of select assets of Labcorp's early-development device-testing business, among them biocompatibility, microbiological and analytical testing. By NAMSA's count in that report, it had made ten acquisitions since 2020, the year in which ARCHIMED, a French private-equity firm in health care, bought a majority of NAMSA.
One owner can also hold a laboratory beside other device services. In its filing of 6 August 2026, Sotera Health reports three segments: Sterigenics in sterilization, Nordion in cobalt-60 and Nelson Labs in testing laboratories. Because laboratories are bought and held in groups like these, a laboratory named in a plan can change owner or name before its report is issued. This book therefore records a laboratory's owner with its date, as it does a material's.
Two recognitions bear on what a laboratory's results can support in a file, and each answers its own question. ISO/IEC 17025 sets out requirements for "the competence, impartiality, and consistent operation of laboratories", and accreditation bodies use it as "the criteria for assessing and accrediting laboratories". Accreditation to it is granted for the test methods named on a laboratory's scope, so it answers whether the laboratory is competent to run a given method. Good Laboratory Practice, or GLP, governs how a nonclinical safety study is planned, run, recorded and archived. In the United States its rules are 21 CFR 58, which "prescribes good laboratory practices for conducting nonclinical laboratory studies" that support applications to FDA, for medical devices among other products. Neither recognition says that a material or a device is safe, since a competent laboratory can run a well-recorded study on a material that fails it.
FDA treats the two recognitions differently. Its 2023 guidance on ISO 10993-1 asks that biological safety tests be conducted in accordance with recognized GLP regulations (Chapter 22). A footnote to that request states that FDA does not recognize ISO/IEC 17025, the standard for the competence of testing and calibration laboratories. The standard enters FDA's review through a voluntary scheme, ASCA, the Accreditation Scheme for Conformity Assessment. The scheme works in three steps: FDA recognizes accreditation bodies, those bodies assess laboratories to ISO/IEC 17025:2017 and to the scheme's own specifications, and FDA then grants ASCA accreditation in areas that include the biocompatibility standards. In its guidance for that area, of 25 September 2020, FDA states that biocompatibility testing under the scheme "will be conducted in accordance with 21 CFR 58". A laboratory testing biocompatibility under ASCA therefore works to both recognitions at once.
FDA's own pages describe the scheme's status in different terms. According to the page of FDA's ASCA guidance for biocompatibility, ASCA's pilot became a permanent program on 19 September 2023. FDA's main ASCA page, current as of 28 January 2026, does not call the scheme permanent. In November 2026 the guidance page also states that the guidance is under revision. Since 18 September 2025 FDA has not accepted ASCA summary test reports from laboratories marked "FDA Initiated Withdrawal".
Evaluators judge the device
The evaluator writes the biological evaluation plan, signs its report and draws the conclusion about the device (Chapter 22). The role joins work that earlier chapters kept apart. The evaluator sorts the device's contacts, reads the chemistry of its materials, decides which tests the chemistry still leaves necessary and weighs every result against the device's use (Chapters 2, 12, 13 and 18). Toxicologists supply the step that turns an identified compound into a judgment. They derive a tolerable intake from a study's point of departure and set the dose that arrives against it as a margin of safety (Chapters 14 and 15).
The competence the role needs follows from that work. FDA's guidance asks for competent, trained staff to run the tests (Chapter 22). The evaluator's work sets demands of its own. The evaluator needs enough chemistry to judge an extractables table and its unknown peaks, enough toxicology to check a tolerable intake and a margin, and enough knowledge of the device's materials and use to see when a tested sample was not the finished device.
India's testing layer
India's testing layer rests on a public institute and three separate recognitions. The institute is SCTIMST, the Sree Chitra Tirunal Institute for Medical Sciences and Technology, in Thiruvananthapuram. Its Biomedical Technology Wing offers testing and biological evaluation of devices and biomaterials to industry and academia, by the institute's own account. The tests listed in the institute's articles of 2023 run from cytotoxicity and sensitization to implantation and genotoxicity, and the articles call the service accredited without naming the accreditation. The first recognition is registration: the Central Drugs Standard Control Organization, CDSCO, registers the laboratories that test devices on a maker's behalf, on Form MD-40. The second is accreditation to ISO/IEC 17025, which in India comes from NABL, the National Accreditation Board for Testing and Calibration Laboratories. The third is GLP certification of test facilities, by the National GLP Compliance Monitoring Authority. Chapter 28 sets out the three recognitions and their rules.
What is moving, and how a laboratory is chosen
Three changes to the method are told in the chapters that own them. Chapter 18 covers methods without animals for skin and genetic damage, and the 3Rs. Chapter 21 covers the 2025 edition of ISO 10993-1, which makes the evaluation a biological risk estimate. Chapter 7 covers the third edition of ISO 10993-7, on ethylene oxide residuals, published on 20 April 2026.
A laboratory is chosen against the evaluation plan, and this book takes its criteria from the plan. Where the file relies on accreditation, as a submission under ASCA does, each test the plan names should appear on the laboratory's accreditation scope. Each safety study should follow GLP where the regulator asks for it. The recognitions should also be those that the file's regulator uses: ASCA accreditation for an FDA submission that relies on the scheme, and for a file in India the recognitions of Chapter 28. Each recognition is checked at its source on the day of the study, because an accreditation can be withdrawn and a published list can be months old.
The last criteria concern who does the work. Under ASCA a maker's in-house laboratory may take part if its impartiality is protected, and a laboratory that passes a test to a subcontractor must use one that is itself ASCA-accredited. The solved example applies the subcontracting rule to the cushion's plan. The questions to put to a laboratory and to an evaluator about a finished report are those of Chapter 24.
- The plan. The book's plan for the silicone cushion runs 3 tests: cytotoxicity, irritation on reconstructed human epidermis and the local lymph node assay in mice (Chapters 18 and 21).
- The checks. Each test needs 2 checks, its method on the site's ISO/IEC 17025 scope and its study conducted to 21 CFR 58. Each site needs 1, its ASCA accreditation on the day.
- One site. A laboratory whose scope lists all 3 methods needs 3 × 2 + 1 = 7 checks.
- Two sites. If its scope lists only 2, the third test may go only to an ASCA-accredited subcontractor, whose own status check makes 8.
- The result. The laboratory is chosen if its scope covers all 3 methods or its subcontractor holds ASCA accreditation on the day; otherwise the third test goes to another laboratory.
- Assumptions. A US file that uses ASCA; the plan, which is this book's choice; and all 3 methods within the scheme's scope, which FDA's ASCA pages do not list method by method.
Write the evaluation plan before choosing a laboratory, with one row for each test: its method, the recognitions the target regulator expects, the site that will run it and the day each recognition was checked. Put the supplier question in writing whenever a material's maker changes owner or name. For the running device it goes to the suppliers of the polycarbonate, the thermoplastic elastomer, the polyether polyurethane foam and the cushion's silicone.
- Makers state what a material is and how they screened it, laboratories measure release and response, and evaluators draw the conclusion on the device.
- Covestro, Elkem's silicones and Trinseo changed owner or status between December 2025 and May 2026, and contract laboratories are consolidating. Every company fact in a file therefore carries its date, and after each change of owner or name the device maker asks the supplier whether the material changed.
- ISO/IEC 17025 accreditation shows a laboratory's competence for a method, GLP governs how a nonclinical safety study is planned, run, recorded and archived, and neither says the device is safe.
- India's testing layer combines SCTIMST's testing wing with three recognitions that Chapter 28 sets out, and in any country a laboratory is chosen against the plan, by recognitions checked on the day.
Let's Talk